Table 2.
Risks of Pregnancy Outcomes by Exposure Group (Truven Health MarketScan® Commercial Claims & Encounters Database, USA, 2011–2014, N=46,365)
| Pregnancy Outcome | Unexposed Pregnancies (n=42,150) | Tretinoin-Exposed Pregnancies (n=4,077) | Isotretinoin-Exposed Pregnancies (n=138) |
|---|---|---|---|
| Livebirth | 31,547 (74.8%) | 2,963 (72.7%) | 68 (49.3%) |
| Spontaneous Abortion | 7,823 (18.6%) | 685 (16.8%) | 30 (21.7%) |
| Elective Termination | 2,487 (5.9%) | 400 (9.8%) | 38 (27.5%) |
| Unspecified Abortion | 136 (0.3%) | 16 (0.4%) | <11 |
| Stillbirth | 157 (0.4%) | 13 (0.3%) | <11 |
| Infant Malformationsa | 631 (4.2%) | 65 (4.5%) | <11 |
a
Among eligible pregnancies. Pregnancies eligible for infant malformation assessment were stillbirth pregnancies, livebirths with linked infants continuously enrolled for the 90 days after delivery, or livebirths with linked neonatal deaths; n=1,430 tretinoin-exposed pregnancies, n=18 isotretinoin-exposed pregnancies, n=14,879 unexposed pregnancies